Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1994 Jan 8;308(6921):72–74. doi: 10.1136/bmj.308.6921.72

Who benefits from medical interventions?

G D Smith, M Egger
PMCID: PMC2539180  PMID: 8298415

Full text

PDF
72

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  2. Alderman M. H. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med. 1993 Aug 15;119(4):329–335. doi: 10.7326/0003-4819-119-4-199308150-00013. [DOI] [PubMed] [Google Scholar]
  3. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. doi: 10.1016/0140-6736(90)90944-z. [DOI] [PubMed] [Google Scholar]
  4. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  5. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  6. Hamilton J. D., Hartigan P. M., Simberkoff M. S., Day P. L., Diamond G. R., Dickinson G. M., Drusano G. L., Egorin M. J., George W. L., Gordin F. M. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992 Feb 13;326(7):437–443. doi: 10.1056/NEJM199202133260703. [DOI] [PubMed] [Google Scholar]
  7. Horton R. Attacks on heart diseases. Lancet. 1993 Nov 20;342(8882):1291–1292. doi: 10.1016/0140-6736(93)92375-4. [DOI] [PubMed] [Google Scholar]
  8. Jackson R., Barham P., Bills J., Birch T., McLennan L., MacMahon S., Maling T. Management of raised blood pressure in New Zealand: a discussion document. BMJ. 1993 Jul 10;307(6896):107–110. doi: 10.1136/bmj.307.6896.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Laupacis A., Sackett D. L., Roberts R. S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988 Jun 30;318(26):1728–1733. doi: 10.1056/NEJM198806303182605. [DOI] [PubMed] [Google Scholar]
  10. McIsaac W. J., Naylor C. D., Basinski A. Mismatch of coronary risk and treatment intensity under the National Cholesterol Education Program guidelines. J Gen Intern Med. 1991 Nov-Dec;6(6):518–523. doi: 10.1007/BF02598220. [DOI] [PubMed] [Google Scholar]
  11. Merigan T. C., Amato D. A., Balsley J., Power M., Price W. A., Benoit S., Perez-Michael A., Brownstein A., Kramer A. S., Brettler D. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. Blood. 1991 Aug 15;78(4):900–906. [PubMed] [Google Scholar]
  12. Naylor C. D., Chen E., Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992 Dec 1;117(11):916–921. doi: 10.7326/0003-4819-117-11-916. [DOI] [PubMed] [Google Scholar]
  13. Oddone E. Z., Cowper P., Hamilton J. D., Matchar D. B., Hartigan P., Samsa G., Simberkoff M., Feussner J. R. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ. 1993 Nov 20;307(6915):1322–1325. doi: 10.1136/bmj.307.6915.1322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Oliver M. F. Sounding board. Risks of correcting the risks of coronary disease and stroke with drugs. N Engl J Med. 1982 Feb 4;306(5):297–298. doi: 10.1056/NEJM198202043060511. [DOI] [PubMed] [Google Scholar]
  15. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  16. Smith G. D., Song F., Sheldon T. A. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993 May 22;306(6889):1367–1373. doi: 10.1136/bmj.306.6889.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Strasser T. Equal blood pressure levels carry different risks in different risk factor combinations. J Hum Hypertens. 1992 Aug;6(4):261–264. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES